Annals of Tropical Medicine and Public Health
Home About us Ahead Of Print Instructions Submission Subscribe Advertise Contact e-Alerts Editorial Board Login 
Users Online:1495
  Print this page  Email this page Small font sizeDefault font sizeIncrease font size

Table of Contents   
Year : 2017  |  Volume : 10  |  Issue : 6  |  Page : 1840-1841
Cutaneous leishmaniasis situation at present and the way of ahead

Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Click here for correspondence address and email

Date of Web Publication11-Jan-2018

How to cite this article:
Tavana AM. Cutaneous leishmaniasis situation at present and the way of ahead. Ann Trop Med Public Health 2017;10:1840-1

How to cite this URL:
Tavana AM. Cutaneous leishmaniasis situation at present and the way of ahead. Ann Trop Med Public Health [serial online] 2017 [cited 2020 Jul 12];10:1840-1. Available from:

Cutaneous leishmaniasis (CL) as an important public health concern in many parts of the world (Africa, Indian subcontinent, eastern and southern west of Asia).[1] The leishmaniasis is present in at least 98 countries and territories, with 1.2 million new cases per year, making it a worldwide concern.[2] There are three forms of leishmaniasis: cutaneous, mucocutaneous, and visceral leishmaniasis. Among these, cutaneous leishmaniasis is more prevalent, particularly, in the tropical and semitropical parts of the world.[3] The disease could be transmitted to human via different female sand flies, particularly Phlebotomus papatasi and Phlebotomus sergenti.[4] Depending on the area and location, different animals are sources of infection, particularly dogs and rodents.[5],[6] Human-to-human transmission via female blood sucking is also possible. The disease has ancient history and different Islamic and Iranian physicians like Avicenna (described in the 10th century AD) have mentioned that in their books.[7] Many researches have been focused in different aspects of the disease, particularly preparation of vaccine like KLM (kill leishmaniasis vaccine),[8],[9],[10],[11],[12],[13],[14] vector control,[15],[16] and treatment.[17]

Unfortunately, it should be emphasized that there is no good news from all researches for public yet. There is no effective candidate vaccine in spite of many works in different countries under supervision of WHO, and vector is very hard and costly and there is no 100% effective medicine for the patients at present. Still much works needs to be done and problems overcome. However, leishmanization (use of alive parasite under standard preparation) is only way used in different infected countries in order to control the infection. In our study, the program was effective nearly 86%.[18],[19],[20] Its standard preparation needs to be improved to possibly increase its effective percentage too. It is good for international health organization to support the program at present time while other control measures become available.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

World Health Organization. Leishmaniasis: background information. A brief history of the disease. 2009. Available at: [Last accessed on 2016 Sep 01].  Back to cited text no. 1
Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous mucocutaneous leishmaniasis: clinical perspectives. J Am Acad Dermatol 2015;73:897-8. quiz 909-10. doi:10.1016/j.jaad.2014.08.051.  Back to cited text no. 2
World Health Organization. Control of the leishmaniasis. Report of a Meeting of the WHO Export Committee on the Control of Leishmaniasis, WHO Technical Report Series 949. Geneva; 2010.  Back to cited text no. 3
Aghae Afshar A, Rassi Y, Sharifi I, Abai MR, Oshaghi MA, Yaghoobi-Ershadi MR. Susceptibility status of Phlebotomus papatasi and P. sergenti (Diptera: Psychodidae) to DDT and deltamethrin in a focus of cutaneous leishmaniasis after earthquake strike in Bam, Iran. Iran J Arthropod Borne Dis 2011;5:32-41.  Back to cited text no. 4
Baneth G, Nachum-Biala Y, Shabat Simon M, Brenner O, Gaier S, Rojas A, Yasur-Landau D. Leishmania major infection in a dog with cutaneous manifestations. Parasit Vectors 2016;9:246- doi:10.1186/s13071-016-1541-2.  Back to cited text no. 5
Yaghoobi-Ershadi MR, Marvi-Moghadam N, Jafari R, Akhavan AA, Solimani H, Zahrai-Ramazani AR. Some epidemiological aspects of cutaneous leishmaniasis in a new focus, central Iran. Dermatol Res Pract 2015 2015;286408- doi:10.1155/2015/286408.  Back to cited text no. 6
Bray RS. Note on the history of cutaneous leishmaniasis in the Mediterranean and Middle East area. Parassitologia 1987;29:175-9.  Back to cited text no. 7
Arjmand R, Fard SS, Saberi S, Tolouei S, Khamesipour A, Hejazi SH. Antigenic profile of heat-killed versus thimerosal-treated leishmania major using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Adv Biomed Res 2015;4:128- doi:10.4103/2277-9175.158068.  Back to cited text no. 8
Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S. Leishmanization: use of an old method for evaluation of candidate vaccines against Leishmaniasis. Vaccine 2005;23:3642-8.  Back to cited text no. 9
Khamesipour A, Rafati S, Davoudi N, Mahboudi F, Modabber F. Leishmaniasis vaccine candidates for development: global overview. Indian J Med Res 2006;123:423-38.  Back to cited text no. 10
Mahmoodi M, Khamesipour A, Dowlati Y, Rafati S, Momeni A, Emamjomehi M. Immune response measured in human volunteers vaccinated with autoclaved leishmania major vaccine mixed with low dose of BCG. Clin Exp Immunol 2003;134:303-8.  Back to cited text no. 11
Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008;26:1709-24. doi: 10.1016/j.vaccine.2008.01.023. Epub 2008 Jan 30. Review. PubMed PMID: 18295939.  Back to cited text no. 12
Shama U, Singh S. Immunobiology of leishmaniasis. Indian J Exp Bio 2009;47:412-23.  Back to cited text no. 13
Fesharki RH, Agha SA, Ahourai P, Djavadian E, Taghavi A, Golabi A. Vaccine preparation and quality control of killed leishmania major. Arch Inst Razi 1992;43:39-50.  Back to cited text no. 14
Nadim A, Motabar M, Houshmand B, Keyghobadi K, Aflatoonian MR. Evaluation of pyrethroid impregnated bednets for control of anthroponotic cutaneous leishmaniasis in Bam (Islamic Republic of Iran). World Health Organization/Leish/95.37. Geneva; 1995.  Back to cited text no. 15
Rassi Y, Abai MR, Javadian E, Rafizadeh S, Imamian H, Mohebali M. Molecular data on vectors and reservoir hosts of zoonotic cutaneous leishmaniasis in central Iran. Bull Soc Path Exot 2008;101:425-28.  Back to cited text no. 16
Copeland NK, Aronson NE. Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis 2015;28:426-37. doi:10.1097/QCO.0000000000000194  Back to cited text no. 17
Tavana AM, Mohebali M, Javadian E, Esfahani AA, Hajjaran H. Leishmanization in small white mice. J Med Sci 2006;6:253-56. doi:10.3923/jms.2006.253.256.  Back to cited text no. 18
Nadim A, Javadian E. Leishmanization in the Islamic Republic of Iran. In: Walton B, Wijeyravetne PM, Modabber F, editors. Research on control strategies for the leishmaniasis. Ottawa: International Development Research Centre; 1998. pp. 336-39.  Back to cited text no. 19
Tavana AM. Why cutaneous leishmaniasis could not be prevented completely? An open discussion. Ann Trop Med Public Health 2011;4:52-3.  Back to cited text no. 20
  [Full text]  

Correspondence Address:
Ali Mehrabi Tavana
Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1755-6783.222646

Rights and Permissions


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *


 Article Access Statistics
    PDF Downloaded18    
    Comments [Add]    

Recommend this journal